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onstruction of chimeric shark antibody fragment binding p24
ucleocapsid protein for detection of antibodies for immunod-
ﬁciency virus type 1 in serum using hemagglutination
. Davila1,∗, T. Camacho2, N. Castillo3, P. Lugo2, E. Sanchez2, A.
icea Navarro2
Universidad Autonoma de Baja California, Tijuana, Mexico
CICESE, Ensenada, Mexico
Universidad Autónoma de Baja California, Tijuana, Mexico
Background: It has been studied that shark antibodies or anti-
ody fragments are important tools for experimental research
nd medical application. The advantages of using these sorts of
olecules are their small size, high solubility and good tissue pen-
tration in vivo. A chimeric shark antibody fragment binding p24
ucleocapsid protein was successfully constructed for HIV detec-
ion. The aim of this research was to determine the presence of
ntibodies for immunodeﬁciency virus type 1 in serum through ex
ivo hemagglutination.
Methods: Using a shark gene that codiﬁes a antibody fragment
apable of recognising glycophorin A from erythrocytes mem-
rane, was obtained from a non immune shark library. The gene
as bind with p24 gene using a double cloning method in order
o construct a chimeric gene. A recombinant chimeric protein
as produced cloning the chimeric gene in an expression vector
hrough Escherichia coli. The effectiveness of the chimeric protein
as evaluated carrying out hemagglutination assays. Erythrocytes
ree of plasma and serum were subjected to a series of wash phos-
hate buffers and 38 HIV positive serum samples donated by the
APASITS clinic, Tijuana B. C. México, were analysed.
Results: The p24 gen was isolated from clinical samples, ampli-
ed and ligated to both the vector carrier and the shark gene. An
nzyme-linked immunobsorbent assay (ELISA) was performed to
he chimeric protein with the aim of verifying the presence of
24 and recognition of glycophorins. Once the functionality of the
himeric proteinwas conﬁrmed, the38HIVpositive serumsamples
ere submitted to hemagglutination assays. Positive results were
btained in 36 samples out of 38,which represent 95% of efﬁciency.
Conclusion: These ﬁndings indicate the efﬁciency of using this
himeric protein for detection of antibodies for immunodeﬁciency
irus type 1 in serum and the possibility to carry out further
esearch inwhole blood samples aswell as anotherHIV type. Also, a
iable potential HIV-1 rapid diagnosis test, aiming it to rural clinical
ractice for it is easy to perform without any special equipment.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.516fectious Diseases 16S (2012) e317–e473 e391
Type: Poster Presentation
Final Abstract Number: 55.006
Session: Diagnostics
Date: Saturday, June 16, 2012
Time: 12:45-14:15
Room: Poster & Exhibition Area
AnalysisofRT-PCRdatabasedontheSmartFinderTMtechnology
using BioNumerics®
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2 PathoFinder B.V., Maastricht, Netherlands
Background: Acute respiratory tract infection is the most
widespread type of acute infection in adults and children and can
be caused by both viruses and bacteria. The number of causative
pathogens is large as well as diverse. Molecular diagnostics play
an increasingly important role in the detection of the responsible
infectious agents. Up to now, multiplex Real Time PCR assays are
able to detect up to 5 targets in one reaction. The RespiFinder®
SMART 22 assay enables the detection of 22 respiratory pathogens
in a Real Time PCR reaction.
Methods: The RespiFinder® SMART 22 assay, developed by
PathoFinder BV, has been designed for the detection and differ-
entiation of 22 respiratory pathogens (18 viruses and 4 bacteria)
and is based on the SmartFinder technology. The technology uses
speciﬁcprobeswhichare ligatedafterhybridization to their respec-
tive target gene and subsequently ampliﬁed and identiﬁed by melt
curve analysis on a Real Time PCR instrument. In the assay, the
SmartFinder reaction is preceded by a pre-ampliﬁcation step with
ensures the detection of the pathogens with the same sensitivity
and speciﬁcity as singleplex Real Time PCR.
Results: We developed a SmartFinder plugin tool in the
BioNumerics® software suite for the analysis of SmartFinder melt
curves. The plugin accepts melt curves from LightCycler 480
(Roche) and Rotor-Gene (Corbett/Qiagen) instruments and pro-
vides a high degree of automation, from the import of raw melt
curve data, to clear reporting of results and indication of prob-
lem cases. BioNumerics’ extensive databasing capabilities allow
for integration with laboratory information management systems
(LIMS), user management and audit trails. In addition, the software
is fully scriptable to achieve any degree of further customization.
Conclusion: With the RespiFinder® SMART 22 assay, 18 viral
and 4 bacterial respiratory pathogens can be detected and dif-
ferentiated in 6 hours, with the same sensitivity and speciﬁcity
as singleplex Real Time PCR. In combination with the automated
workﬂow provided by the SmartFinder plugin of BioNumerics®,
this makes it a valuable tool for high throughput analysis and for
use in hospital settings,where reporting and integrationwith other
systems is often required.
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